{%languageSelectorLabel%}
{%activeLanguage%}This website is for UK Healthcare Professionals only
UK-VNCCLL-210585. Date of Preparation: January 2022.
About the latest data for VENCLYXTO® in Chronic Lymphocytic Leukaemia (CLL)
To receive the latest AbbVie information on upcoming congresses
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-VNCCLL-220175. Date of preparation: May 2022.
To direct you to the most appropriate information, please confirm:
I am a UK Healthcare Professional.
This AbbVie website is intended for UK Healthcare Professionals only and contains promotional content.
I am a member of the public based in the UK
Report adverse events (healthcare professionals in the UK)
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie at GBPV@abbvie.com
UK-ABBV-220399. Date of preparation: June 2022
Reporting of side effects (patients and public in the UK)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.
For medicines with black triangle:
▼ means the medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects.
UK-ABBV-220400. Date of preparation: June 2022.